Spero Therapeutics appoints William Ho to board and Development Committee
SPRO•Spero Therapeutics appointed William Ho to its board and Development Committee effective November 10, 2026. Patrick Vink stepped down after 11 years on the board.
1. Board changes
Spero Therapeutics appointed William Ho to its board and Development Committee effective November 10, 2026. Ho brings more than 20 years of clinical development experience; Patrick Vink stepped down concurrently after 11 years of service.
2. Recent appointments
Debra Jeske Zack became chief medical officer in July 2026, after previously holding the role at Exagen. Amy Rock was recently appointed chief regulatory and quality officer to lead global regulatory strategy, quality and pharmacovigilance.
